1. Diagnostic strategies with adapted D-dimer thresholds safe and efficient for ruling out acute pulmonary embolism, even in high-risk patients Abstract: https://www ...

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading across many parts of the world, and clinicians are working on recognizing biomarkers ...

Tampa, FL (Oct. 26, 2021) --A screening blood test originally validated in seriously ill patients without COVID-19 is still clinically useful for ruling out pulmonary embolism in patients hospitalized ...

Although D-dimer results within a typical range can rule out pulmonary embolism, high results alone can’t diagnose this condition. Doctors usually need to run extra tests to make a diagnosis. A ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than one-quarter of patients with COVID-19 had ...

Using D-dimer tests to evaluate low-risk patients allows for anticoagulation duration to be adjusted on a case-by-case basis. Recurrent venous thromboembolism (VTE) occurs in as many as 30% of ...

Use of clinical decision rules in conjunction with D-dimer thresholds adjusted higher based on either age or pretest probability is acceptably safe for ruling out acute pulmonary embolism (PE) without ...

A targeted computerized alert at the time of physician order entry reduced the use of D-dimer testing among patients 65 years and older. A single-crossover cluster randomized trial of computerized ...

The finding was independent of a range of other biomarkers and standard risk factors and suggests that D-dimer, which reflects fibrinolytic activity as a marker of conditions predisposing to ...

Feasibility of a prospective host cell reactivation assay (HCRA) in non-small cell lung cancer (NSCLC) patients. Background: Procoagulant changes in the haemostatic system and activation of ...